HTG Receives First Order For HTG Transcriptome Panel, Enters Two European EAP Agreements

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe.
The company continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.
Entering into additional EAP agreements allows for further studies, which HTG believes will validate its Transcriptome Panel's performance requirements.
Price Action: HTGM shares are up 4.2% at $5.34 during the market session on the last check Tuesday.

To add Benzinga News as your preferred source on Google, click here.

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe.
The company continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.
Entering into additional EAP agreements allows for further studies, which HTG believes will validate its Transcriptome Panel's performance requirements.
Price Action: HTGM shares are up 4.2% at $5.34 during the market session on the last check Tuesday.

To add Benzinga News as your preferred source on Google, click here.